"我们研究发现NK细胞作为免疫效应细胞，其活性受到细胞表面表达的多种活化性和抑制性受体的调 控，通过这些受体能够天然识别正常细胞和肿瘤细胞，进而启动多重抗肿瘤免疫应答。"天港医诺CEO 孙昊昱在接受记者采访时表示，这一特性使NK细胞的受配体成为潜在的免疫检查点靶点，也是天港医 诺进行药物开发的理论依据。 "上述两款药物进入临床入组给药阶段是公司发展的重要里程碑。我们将持续推动更多'中国智造'创新 疗法从实验室走向临床，让全球肿瘤患者早日受益于这些突破性成果。"孙昊昱表示，天港医诺未来计 划继续推进临床管线的开发，预计每年有1个至2个产品进入临床研究阶段，并积极推进项目海外授权， 目前已与全球数家跨国药企保持密切联系。 本报讯(记者徐一鸣)近期，两款针对NK细胞靶点研发的创新免疫药物，先后在北京大学肿瘤医院、复 旦大学附属肿瘤医院启动Ⅰ期临床试验，并均完成首例患者入组与给药。 具体来看，双特异性抗体药物为国内首款进入临床阶段的同靶点产品，目前，全球尚无同类药物获批， 对结直肠癌及其他靶点阳性实体瘤具有治疗潜力。另一款单克隆抗体药物可覆盖肝癌、黑色素瘤等多个 适应症。相关成果均来自合肥天港免疫药物有限公司(以下简 ...

Group 1 - The stock price of Maiwei Biotech-U is reported at 33.09 yuan, down by 0.71 yuan from the previous trading day, with a trading volume of 4.27 billion yuan [1] - Maiwei Biotech-U operates in the biopharmaceutical industry, focusing on the research, production, and sales of antibody drugs, including monoclonal antibodies and bispecific antibody drugs [1] - The company announced the completion of the first patient dosing in the clinical trial of its innovative drug 9MW2821 targeting Nectin-4ADC for patients with ADC-treated triple-negative breast cancer in the United States, marking its first overseas clinical trial [1] Group 2 - On August 12, the net outflow of main funds was 46.4564 million yuan, with a cumulative net outflow of 218 million yuan over the past five days [1]